What Happens When You Stop Semaglutide or Tirzepatide? The Weight-Regain Data You Need to Know

If you're on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), you've probably wondered what happens if you ever stop. Maybe it's the cost, a supply issue, side effects, or your doctor talking about a "maintenance phase." Whatever the reason, the question deserves a real answer, and in the last few months, we've gotten some of the best data yet. As an Internal Medicine physician, I want to walk you through what the actual research shows, not the scary headlines or the marketing claims.

Why This Question Matters Right Now

GLP-1 medications have gone from a niche diabetes drug class to one of the most widely prescribed treatments in the country, and a huge share of patients on them eventually pause or stop, whether by choice, cost, insurance denial, or side effects. Understanding what happens next isn't optional information anymore; it's something every patient starting one of these medications should discuss with their doctor before they ever fill the first prescription.

• Cost and insurance coverage remain the most common reasons patients stop

• GI side effects (nausea, constipation) cause a meaningful share of early discontinuations

• Many patients assume stopping simply means "staying at their new weight," which the data does not support

  
  

The Clinical Trial Data: STEP 1 and SURMOUNT-4

The clearest evidence comes from the extension phases of the original trials. In the STEP 1 trial extension, participants who lost an average of 17.3% of their body weight on semaglutide over 68 weeks regained roughly two-thirds of that lost weight within a year of stopping the drug and lifestyle support. Their blood pressure, cholesterol, and blood sugar improvements reversed toward baseline along with the weight regain, not completely, but substantially.

Tirzepatide tells a similar story. A post hoc analysis of the SURMOUNT-4 trial, published in JAMA Internal Medicine in 2026, found that among patients who had lost at least 10% of their body weight, 82.5% had regained at least a quarter of that lost weight by week 88 after stopping the medication, and cardiometabolic improvements reversed right along with it.

• STEP 1 extension: ~11.6 percentage points of the ~17.3% lost were regained within a year off semaglutide

• SURMOUNT-4: 82.5% of tirzepatide responders regained ≥25% of lost weight by week 88

• In both trials, patients who stayed on treatment kept the large majority of their weight loss

  
  

Real-World Practice Tells a More Nuanced Story

Clinical trials are controlled environments; real clinics are messier, and sometimes that's a good thing. A 2026 Cleveland Clinic study in Diabetes, Obesity and Metabolism followed nearly 8,000 patients who stopped semaglutide or tirzepatide in routine practice. The average weight change one year later was more modest than the trial data would predict, largely because many patients didn't just stop and walk away. They restarted the original medication, switched to an alternative treatment, or leaned harder on lifestyle support.

This is an important nuance: the regain seen in trials often assumes no further intervention. In real life, most patients and their doctors adjust course, which changes the outcome considerably.

• Real-world regain was smaller on average than in the tightly controlled trial extensions

• Reinitiating therapy or switching medications after stopping was common and effective

• Individual variability was considerable, some patients maintained their loss well, others did not

  
  

Why the Weight Comes Back: Obesity as a Chronic, Relapsing Disease

This isn't a willpower problem, and it isn't unique to GLP-1 medications. When you lose a significant amount of weight, your body responds with changes designed to defend its prior set point: appetite-suppressing hormones like GLP-1 and PYY drop, hunger-driving ghrelin rises, and resting energy expenditure falls below what your new body weight would predict. GLP-1 drugs work in large part by directly counteracting that biology. Remove the medication, and the underlying biological pressure to regain doesn't disappear, it simply loses its counterweight.

This is exactly why major obesity medicine organizations now describe obesity as a chronic disease requiring long-term management, similar to hypertension or diabetes, rather than a problem that gets permanently "solved" after a course of treatment.

• The body's hunger and metabolism hormones actively resist weight loss, this doesn't turn off when you feel "done"

• GLP-1 medications treat an underlying biological driver, not just a symptom

• Framing obesity as chronic, rather than acute, changes how stopping medication should be planned

If You're Stopping (or Might Have To), Here's How to Protect Your Progress

Whether you're stopping by choice or circumstance, there are concrete steps that meaningfully change the odds. Preserving lean muscle mass matters most, patients who maintain resistance training and adequate protein intake while on and after these medications tend to hold onto their results better than those who don't. A gradual taper, rather than an abrupt stop, may also help some patients, though this should always be physician-guided.

• Prioritize protein intake and resistance training throughout treatment and after stopping

• Ask your doctor about a gradual dose taper instead of stopping abruptly, if appropriate for you

• Build the lifestyle habits (sleep, stress management, structured eating) during treatment, not after

Talking to Your Doctor About a Taper or Maintenance Plan

The biggest mistake I see is patients treating GLP-1 therapy as a fixed-length "course," like a round of antibiotics, rather than an ongoing treatment for a chronic condition. Before you stop for any reason, have a specific conversation with your physician about a maintenance plan: Will you taper the dose? Switch to a lower maintenance dose? Lean on an alternative therapy? Increase behavioral support? These decisions are far easier to make proactively than reactively after regain has already started.

• Ask specifically: "What is our plan if I need to stop or reduce this medication?"

• A lower maintenance dose is sometimes an option instead of full discontinuation

• Don't wait for regain to start the conversation, plan for it in advance

The Bottom Line

Stopping semaglutide or tirzepatide doesn't erase your progress overnight, but the honest, evidence-based answer is that meaningful weight regain is common without a follow-up plan, both in tightly controlled trials and in everyday practice. The good news is that regain isn't inevitable: real-world data shows that patients who stay engaged with their care team, whether through restarting therapy, switching treatments, or doubling down on muscle-preserving habits, tend to do better than the trial numbers alone would suggest. If you're considering stopping, or if life circumstances are forcing the decision, don't do it in a vacuum. Talk to your doctor about a real plan first.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice. Always consult your physician before starting, stopping, or changing any medication or health regimen.

Sources cited

• Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension." Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. PMID: 35441470.

• "Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial." JAMA Internal Medicine. 2026. PMID: 41284285.

• Gasoyan H, et al. "Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide." Diabetes, Obesity and Metabolism. 2026. PMID: 41816857.

• CDC National Diabetes Statistics Report, 2024.